» Articles » PMID: 35054279

Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering

Overview
Specialty Radiology
Date 2022 Jan 21
PMID 35054279
Authors
Affiliations
Soon will be listed here.
Abstract

The second most common progressive neurodegenerative disorder, Parkinson's disease (PD), is characterized by a broad spectrum of symptoms that are associated with its progression. Several studies have attempted to classify PD according to its clinical manifestations and establish objective biomarkers for early diagnosis and for predicting the prognosis of the disease. Recent comprehensive research on the classification of PD using clinical phenotypes has included factors such as dominance, severity, and prognosis of motor and non-motor symptoms and biomarkers. Additionally, neuroimaging studies have attempted to reveal the pathological substrate for motor symptoms. Genetic and transcriptomic studies have contributed to our understanding of the underlying molecular pathogenic mechanisms and provided a basis for classifying PD. Moreover, an understanding of the heterogeneity of clinical manifestations in PD is required for a personalized medicine approach. Herein, we discuss the possible subtypes of PD based on clinical features, neuroimaging, and biomarkers for developing personalized medicine for PD. In addition, we conduct a preliminary clustering using gait features for subtyping PD. We believe that subtyping may facilitate the development of therapeutic strategies for PD.

Citing Articles

Transcriptomics profiling of Parkinson's disease progression subtypes reveals distinctive patterns of gene expression.

Fabrizio C, Termine A, Caltagirone C J Cent Nerv Syst Dis. 2025; 17:11795735241286821.

PMID: 39906346 PMC: 11791511. DOI: 10.1177/11795735241286821.


Microstructural alterations in white matter and related neurobiology based on the new clinical subtypes of Parkinson's disease.

Yuan X, Yu Q, Liu Y, Chen J, Gao J, Liu Y Front Neurosci. 2024; 18:1439443.

PMID: 39148522 PMC: 11324559. DOI: 10.3389/fnins.2024.1439443.


The Role of Non-Invasive Brain Modulation in Identifying Disease Biomarkers for Diagnostic and Therapeutic Purposes in Parkinsonism.

Birreci D, De Riggi M, Costa D, Angelini L, Cannavacciuolo A, Passaretti M Brain Sci. 2024; 14(7).

PMID: 39061435 PMC: 11274666. DOI: 10.3390/brainsci14070695.


Functional neural networks stratify Parkinson's disease patients across the spectrum of cognitive impairment.

Hajebrahimi F, Budak M, Saricaoglu M, Temel Z, Demir T, Hanoglu L Brain Behav. 2024; 14(1):e3395.

PMID: 38376051 PMC: 10808882. DOI: 10.1002/brb3.3395.


Study of the gut microbiome in Egyptian patients with Parkinson's Disease.

Mehanna M, AbuRaya S, Ahmed S, Ashmawy G, Ibrahim A, AbdelKhaliq E BMC Microbiol. 2023; 23(1):196.

PMID: 37481569 PMC: 10362707. DOI: 10.1186/s12866-023-02933-7.


References
1.
Gu Q, Zhang H, Xuan M, Luo W, Huang P, Xia S . Automatic Classification on Multi-Modal MRI Data for Diagnosis of the Postural Instability and Gait Difficulty Subtype of Parkinson's Disease. J Parkinsons Dis. 2016; 6(3):545-56. DOI: 10.3233/JPD-150729. View

2.
Bohnen N, Muller M, Zarzhevsky N, Koeppe R, Bogan C, Kilbourn M . Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. Brain. 2011; 134(Pt 8):2358-65. PMC: 3155702. DOI: 10.1093/brain/awr139. View

3.
Shamir R, Klein C, Amar D, Vollstedt E, Bonin M, Usenovic M . Analysis of blood-based gene expression in idiopathic Parkinson disease. Neurology. 2017; 89(16):1676-1683. PMC: 5644465. DOI: 10.1212/WNL.0000000000004516. View

4.
Choi S, Kim B, Cho B, Kang K, Choi K, Kim J . Comparison of two motor subtype classifications in de novo Parkinson's disease. Parkinsonism Relat Disord. 2018; 54:74-78. DOI: 10.1016/j.parkreldis.2018.04.021. View

5.
Jalali M, Roudbary S, Gerami H, Soleimani R, Ebrahimi S . Olfactory Identification among Various Subtypes of Parkinson Disease. Eur Neurol. 2019; 81(3-4):167-173. DOI: 10.1159/000501551. View